{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:39:20Z","timestamp":1789155560453,"version":"build-2803163510"},"reference-count":146,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T00:00:00Z","timestamp":1733443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T00:00:00Z","timestamp":1733443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"European Union- Next-Generation EU, Greece 2.0 National Recovery and Resilience plan, National Flagship Initiative \"Health and Pharmaceuticals\"","award":["TAEDR-0535850"],"award-info":[{"award-number":["TAEDR-0535850"]}]},{"name":"European Union- Next-Generation EU, Greece 2.0 National Recovery and Resilience plan, National Flagship Initiative \"Health and Pharmaceuticals\"","award":["TAEDR-0535850"],"award-info":[{"award-number":["TAEDR-0535850"]}]},{"name":"European Union- Next-Generation EU, Greece 2.0 National Recovery and Resilience plan, National Flagship Initiative \"Health and Pharmaceuticals\"","award":["TAEDR-0535850"],"award-info":[{"award-number":["TAEDR-0535850"]}]},{"name":"European Union- Next-Generation EU, Greece 2.0 National Recovery and Resilience plan, National Flagship Initiative \"Health and Pharmaceuticals\"","award":["TAEDR-0535850"],"award-info":[{"award-number":["TAEDR-0535850"]}]},{"name":"European Union- Next-Generation EU, Greece 2.0 National Recovery and Resilience plan, National Flagship Initiative \"Health and Pharmaceuticals\"","award":["TAEDR-0535850"],"award-info":[{"award-number":["TAEDR-0535850"]}]},{"name":"European Union- Next-Generation EU, Greece 2.0 National Recovery and Resilience plan, National Flagship Initiative \"Health and Pharmaceuticals\"","award":["TAEDR-0535850"],"award-info":[{"award-number":["TAEDR-0535850"]}]},{"name":"European Union- Next-Generation EU, Greece 2.0 National Recovery and Resilience plan, National Flagship Initiative \"Health and Pharmaceuticals\"","award":["TAEDR-0535850"],"award-info":[{"award-number":["TAEDR-0535850"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"DOI":"10.1186\/s13148-024-01787-8","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T05:28:50Z","timestamp":1733462930000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["BRCA1 & BRCA2 methylation as a prognostic and predictive biomarker in cancer: Implementation in liquid biopsy in the era of precision medicine"],"prefix":"10.1186","volume":"16","author":[{"given":"Maria","family":"Panagopoulou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodoros","family":"Panou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasios","family":"Gkountakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gesthimani","family":"Tarapatzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makrina","family":"Karaglani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Tsamardinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterini","family":"Chatzaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,6]]},"reference":[{"issue":"1","key":"1787_CR1","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/nrc3181","volume":"12","author":"R Roy","year":"2011","unstructured":"Roy R, Chun J, Powell SN. BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer. 2011;12(1):68\u201378.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"1787_CR2","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a016600","volume":"7","author":"R Prakash","year":"2015","unstructured":"Prakash R, Zhang Y, Feng W, Jasin M. Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins. Cold Spring Harb Perspect Biol. 2015;7(4): a016600.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"1787_CR3","doi-asserted-by":"crossref","unstructured":"Guo M, Wang SM. The BRCAness Landscape of Cancer. Cells. 2022;11(23).","DOI":"10.3390\/cells11233877"},{"issue":"5182","key":"1787_CR4","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1126\/science.7545954","volume":"266","author":"Y Miki","year":"1994","unstructured":"Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266(5182):66\u201371.","journal-title":"Science"},{"issue":"1","key":"1787_CR5","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/0168-9525(93)90068-S","volume":"9","author":"DM Black","year":"1993","unstructured":"Black DM, Solomon E. The search for the familial breast\/ovarian cancer gene. Trends Genet. 1993;9(1):22\u20136.","journal-title":"Trends Genet"},{"issue":"23","key":"1787_CR6","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1056\/NEJMra012284","volume":"348","author":"R Wooster","year":"2003","unstructured":"Wooster R, Weber BL. Breast and ovarian cancer. N Engl J Med. 2003;348(23):2339\u201347.","journal-title":"N Engl J Med"},{"key":"1787_CR7","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1200\/EDBK_238977","volume":"39","author":"R Pilarski","year":"2019","unstructured":"Pilarski R. The Role of BRCA Testing in Hereditary Pancreatic and Prostate Cancer Families. Am Soc Clin Oncol Educ Book. 2019;39:79\u201386.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"13","key":"1787_CR8","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1001\/jama.2014.5985","volume":"313","author":"TR Rebbeck","year":"2015","unstructured":"Rebbeck TR, Mitra N, Wan F, Sinilnikova OM, Healey S, McGuffog L, et al. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA. 2015;313(13):1347\u201361.","journal-title":"JAMA"},{"issue":"23","key":"1787_CR9","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA. 2017;317(23):2402\u201316.","journal-title":"JAMA"},{"issue":"2","key":"1787_CR10","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S1470-2045(17)30891-4","volume":"19","author":"ER Copson","year":"2018","unstructured":"Copson ER, Maishman TC, Tapper WJ, Cutress RI, Greville-Heygate S, Altman DG, et al. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. Lancet Oncol. 2018;19(2):169\u201380.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1787_CR11","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1200\/JCO.2010.33.0068","volume":"30","author":"PJ Goodwin","year":"2012","unstructured":"Goodwin PJ, Phillips KA, West DW, Ennis M, Hopper JL, John EM, et al. Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study. J Clin Oncol. 2012;30(1):19\u201326.","journal-title":"J Clin Oncol"},{"key":"1787_CR12","doi-asserted-by":"crossref","unstructured":"Schmidt MK, van den Broek AJ, Tollenaar RA, Smit VT, Westenend PJ, Brinkhuis M, et al. Breast Cancer Survival of BRCA1\/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women. J Natl Cancer Inst. 2017;109(8).","DOI":"10.1093\/jnci\/djw329"},{"issue":"2","key":"1787_CR13","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1093\/jnci\/djab151","volume":"114","author":"AW Kurian","year":"2022","unstructured":"Kurian AW, Abrahamse P, Bondarenko I, Hamilton AS, Deapen D, Gomez SL, et al. Association of Genetic Testing Results With Mortality Among Women With Breast Cancer or Ovarian Cancer. J Natl Cancer Inst. 2022;114(2):245\u201353.","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"1787_CR14","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1001\/jama.2012.20","volume":"307","author":"KL Bolton","year":"2012","unstructured":"Bolton KL, Chenevix-Trench G, Goh C, Sadetzki S, Ramus SJ, Karlan BY, et al. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA. 2012;307(4):382\u201390.","journal-title":"JAMA"},{"issue":"16","key":"1787_CR15","first-page":"3347","volume":"57","author":"A Dobrovic","year":"1997","unstructured":"Dobrovic A, Simpfendorfer D. Methylation of the BRCA1 gene in sporadic breast cancer. Cancer Res. 1997;57(16):3347\u201350.","journal-title":"Cancer Res"},{"issue":"11","key":"1787_CR16","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1038\/sj.onc.1202509","volume":"18","author":"A Catteau","year":"1999","unstructured":"Catteau A, Harris WH, Xu CF, Solomon E. Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene. 1999;18(11):1957\u201365.","journal-title":"Oncogene"},{"issue":"3","key":"1787_CR17","first-page":"387","volume":"23","author":"N Rabiau","year":"2009","unstructured":"Rabiau N, Thiam MO, Satih S, Guy L, Kemeny JL, Boiteux JP, et al. Methylation analysis of BRCA1, RASSF1, GSTP1 and EPHB2 promoters in prostate biopsies according to different degrees of malignancy. In vivo (Athens, Greece). 2009;23(3):387\u201391.","journal-title":"In vivo (Athens, Greece)"},{"issue":"1","key":"1787_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/carcin\/bgp220","volume":"31","author":"S Sharma","year":"2010","unstructured":"Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis. 2010;31(1):27\u201336.","journal-title":"Carcinogenesis"},{"issue":"21","key":"1787_CR19","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1056\/NEJMra023075","volume":"349","author":"JG Herman","year":"2003","unstructured":"Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003;349(21):2042\u201354.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"1787_CR20","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1038\/ncponc0354","volume":"2","author":"SB Baylin","year":"2005","unstructured":"Baylin SB. DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol. 2005;2(Suppl 1):S4-11.","journal-title":"Nat Clin Pract Oncol"},{"issue":"25","key":"1787_CR21","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","volume":"384","author":"ANJ Tutt","year":"2021","unstructured":"Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, et al. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. N Engl J Med. 2021;384(25):2394\u2013405.","journal-title":"N Engl J Med"},{"issue":"1","key":"1787_CR22","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.1002\/onco.13551","volume":"26","author":"S Arora","year":"2021","unstructured":"Arora S, Balasubramaniam S, Zhang H, Berman T, Narayan P, Suzman D, et al. FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer. Oncologist. 2021;26(1):e164\u201372.","journal-title":"Oncologist"},{"issue":"1","key":"1787_CR23","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41523-022-00411-3","volume":"8","author":"N Tung","year":"2022","unstructured":"Tung N, Garber JE. PARP inhibition in breast cancer: progress made and future hopes. NPJ Breast Cancer. 2022;8(1):47.","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"1787_CR24","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13048-023-01094-5","volume":"16","author":"Y Wu","year":"2023","unstructured":"Wu Y, Xu S, Cheng S, Yang J, Wang Y. Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current status. J Ovarian Res. 2023;16(1):6.","journal-title":"J Ovarian Res"},{"issue":"5","key":"1787_CR25","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1200\/JCO.23.00339","volume":"42","author":"J Mateo","year":"2024","unstructured":"Mateo J, de Bono JS, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and\/or BRCA2 in the PROfound Trial. J Clin Oncol. 2024;42(5):571\u201383.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1787_CR26","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1056\/NEJMoa2214676","volume":"388","author":"K Fizazi","year":"2023","unstructured":"Fizazi K, Piulats JM, Reaume MN, Ostler P, McDermott R, Gingerich JR, et al. Rucaparib or Physician\u2019s Choice in Metastatic Prostate Cancer. N Engl J Med. 2023;388(8):719\u201332.","journal-title":"N Engl J Med"},{"issue":"22","key":"1787_CR27","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1200\/JCO.21.00003","volume":"39","author":"KA Reiss","year":"2021","unstructured":"Reiss KA, Mick R, O\u2019Hara MH, Teitelbaum U, Karasic TB, Schneider C, et al. Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, BRCA2, or PALB2. J Clin Oncol. 2021;39(22):2497\u2013505.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1787_CR28","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000019345","volume":"99","author":"S Li","year":"2020","unstructured":"Li S, He Y, Li C, Liu X, Shen Y, Wu Y, et al. The association between the methylation frequency of BRCA1\/2 gene promoter and occurrence and prognosis of breast carcinoma: A meta-analysis. Medicine. 2020;99(10): e19345.","journal-title":"Medicine"},{"issue":"1","key":"1787_CR29","doi-asserted-by":"publisher","first-page":"3970","DOI":"10.1038\/s41467-018-05564-z","volume":"9","author":"O Kondrashova","year":"2018","unstructured":"Kondrashova O, Topp M, Nesic K, Lieschke E, Ho GY, Harrell MI, et al. Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nat Commun. 2018;9(1):3970.","journal-title":"Nat Commun"},{"issue":"6","key":"1787_CR30","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1093\/annonc\/mdt011","volume":"24","author":"Y Xu","year":"2013","unstructured":"Xu Y, Diao L, Chen Y, Liu Y, Wang C, Ouyang T, et al. Promoter methylation of BRCA1 in triple-negative breast cancer predicts sensitivity to adjuvant chemotherapy. Annals of oncology\u202f: official journal of the European Society for Medical Oncology. 2013;24(6):1498\u2013505.","journal-title":"Annals of oncology : official journal of the European Society for Medical Oncology"},{"key":"1787_CR31","doi-asserted-by":"crossref","unstructured":"Sahnane N, Carnevali I, Formenti G, Casarin J, Facchi S, Bombelli R, et al. BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor. Int J Mol Sci. 2020;21(24).","DOI":"10.3390\/ijms21249708"},{"issue":"9","key":"1787_CR32","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.7150\/jca.30410","volume":"10","author":"I Gorodetska","year":"2019","unstructured":"Gorodetska I, Kozeretska I, Dubrovska A. BRCA Genes: The Role in Genome Stability, Cancer Stemness and Therapy Resistance. J Cancer. 2019;10(9):2109\u201327.","journal-title":"J Cancer"},{"issue":"3","key":"1787_CR33","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/nrm2851","volume":"11","author":"ME Moynahan","year":"2010","unstructured":"Moynahan ME, Jasin M. Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis. Nat Rev Mol Cell Biol. 2010;11(3):196\u2013207.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1787_CR34","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.pbiomolbio.2021.03.007","volume":"163","author":"RM Williams","year":"2021","unstructured":"Williams RM, Zhang X. Roles of ATM and ATR in DNA double strand breaks and replication stress. Prog Biophys Mol Biol. 2021;163:109\u201319.","journal-title":"Prog Biophys Mol Biol"},{"issue":"6","key":"1787_CR35","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/nsmb775","volume":"11","author":"JA Clapperton","year":"2004","unstructured":"Clapperton JA, Manke IA, Lowery DM, Ho T, Haire LF, Yaffe MB, et al. Structure and mechanism of BRCA1 BRCT domain recognition of phosphorylated BACH1 with implications for cancer. Nat Struct Mol Biol. 2004;11(6):512\u20138.","journal-title":"Nat Struct Mol Biol"},{"issue":"7","key":"1787_CR36","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1093\/abbs\/gmw047","volume":"48","author":"J Her","year":"2016","unstructured":"Her J, Soo Lee N, Kim Y, Kim H. Factors forming the BRCA1-A complex orchestrate BRCA1 recruitment to the sites of DNA damage. Acta Biochim Biophys Sin. 2016;48(7):658\u201364.","journal-title":"Acta Biochim Biophys Sin"},{"issue":"10","key":"1787_CR37","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1038\/s12276-020-00519-1","volume":"52","author":"F Zhao","year":"2020","unstructured":"Zhao F, Kim W, Kloeber JA, Lou Z. DNA end resection and its role in DNA replication and DSB repair choice in mammalian cells. Exp Mol Med. 2020;52(10):1705\u201314.","journal-title":"Exp Mol Med"},{"issue":"7676","key":"1787_CR38","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/nature24060","volume":"550","author":"W Zhao","year":"2017","unstructured":"Zhao W, Steinfeld JB, Liang F, Chen X, Maranon DG, Jian Ma C, et al. BRCA1-BARD1 promotes RAD51-mediated homologous DNA pairing. Nature. 2017;550(7676):360\u20135.","journal-title":"Nature"},{"issue":"1","key":"1787_CR39","doi-asserted-by":"publisher","first-page":"6728","DOI":"10.1038\/s41467-022-34523-y","volume":"13","author":"JB Shah","year":"2022","unstructured":"Shah JB, Pueschl D, Wubbenhorst B, Fan M, Pluta J, D\u2019Andrea K, et al. Analysis of matched primary and recurrent BRCA1\/2 mutation-associated tumors identifies recurrence-specific drivers. Nat Commun. 2022;13(1):6728.","journal-title":"Nat Commun"},{"key":"1787_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.813457","volume":"10","author":"X Fu","year":"2022","unstructured":"Fu X, Tan W, Song Q, Pei H, Li J. BRCA1 and Breast Cancer: Molecular Mechanisms and Therapeutic Strategies. Front Cell Dev Biol. 2022;10: 813457.","journal-title":"Front Cell Dev Biol"},{"key":"1787_CR41","unstructured":"Petrucelli N, Daly MB, Pal T. BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, et al., editors. GeneReviews((R)). Seattle (WA)1993."},{"key":"1787_CR42","unstructured":"Casaubon JT, Kashyap S, Regan JP. BRCA1 and BRCA2 Mutations. StatPearls. Treasure Island (FL)2024."},{"issue":"12","key":"1787_CR43","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1093\/jnci\/djaa070","volume":"112","author":"RD Kalachand","year":"2020","unstructured":"Kalachand RD, Stordal B, Madden S, Chandler B, Cunningham J, Goode EL, et al. BRCA1 Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis. J Natl Cancer Inst. 2020;112(12):1190\u2013203.","journal-title":"J Natl Cancer Inst"},{"key":"1787_CR44","doi-asserted-by":"publisher","first-page":"4986365","DOI":"10.1155\/2020\/4986365","volume":"2020","author":"C Messina","year":"2020","unstructured":"Messina C, Cattrini C, Soldato D, Vallome G, Caffo O, Castro E, et al. BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications. J Oncol. 2020;2020:4986365.","journal-title":"J Oncol"},{"issue":"10","key":"1787_CR45","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1038\/s41416-021-01469-9","volume":"125","author":"E Lai","year":"2021","unstructured":"Lai E, Ziranu P, Spanu D, Dubois M, Pretta A, Tolu S, et al. BRCA-mutant pancreatic ductal adenocarcinoma. Br J Cancer. 2021;125(10):1321\u201332.","journal-title":"Br J Cancer"},{"key":"1787_CR46","doi-asserted-by":"crossref","unstructured":"Miklikova S, Trnkova L, Plava J, Bohac M, Kuniakova M, Cihova M. The Role of BRCA1\/2-Mutated Tumor Microenvironment in Breast Cancer. Cancers (Basel). 2021;13(3).","DOI":"10.3390\/cancers13030575"},{"issue":"20","key":"1787_CR47","doi-asserted-by":"publisher","first-page":"3828","DOI":"10.1128\/MCB.01646-13","volume":"34","author":"SJ Hill","year":"2014","unstructured":"Hill SJ, Clark AP, Silver DP, Livingston DM. BRCA1 pathway function in basal-like breast cancer cells. Mol Cell Biol. 2014;34(20):3828\u201342.","journal-title":"Mol Cell Biol"},{"issue":"8","key":"1787_CR48","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1016\/j.molonc.2015.04.011","volume":"9","author":"TM Severson","year":"2015","unstructured":"Severson TM, Peeters J, Majewski I, Michaut M, Bosma A, Schouten PC, et al. BRCA1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential. Mol Oncol. 2015;9(8):1528\u201338.","journal-title":"Mol Oncol"},{"issue":"10","key":"1787_CR49","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/s10038-020-0780-4","volume":"65","author":"E Aref-Eshghi","year":"2020","unstructured":"Aref-Eshghi E, McGee JD, Pedro VP, Kerkhof J, Stuart A, Ainsworth PJ, et al. Genetic and epigenetic profiling of BRCA1\/2 in ovarian tumors reveals additive diagnostic yield and evidence of a genomic BRCA1\/2 DNA methylation signature. J Hum Genet. 2020;65(10):865\u201373.","journal-title":"J Hum Genet"},{"issue":"1","key":"1787_CR50","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1038\/s41467-020-16399-y","volume":"11","author":"CA Nichols","year":"2020","unstructured":"Nichols CA, Gibson WJ, Brown MS, Kosmicki JA, Busanovich JP, Wei H, et al. Loss of heterozygosity of essential genes represents a widespread class of potential cancer vulnerabilities. Nat Commun. 2020;11(1):2517.","journal-title":"Nat Commun"},{"issue":"1","key":"1787_CR51","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/s41467-017-00388-9","volume":"8","author":"KN Maxwell","year":"2017","unstructured":"Maxwell KN, Wubbenhorst B, Wenz BM, De Sloover D, Pluta J, Emery L, et al. BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers. Nat Commun. 2017;8(1):319.","journal-title":"Nat Commun"},{"issue":"9","key":"1787_CR52","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.tcb.2019.06.005","volume":"29","author":"AK Byrum","year":"2019","unstructured":"Byrum AK, Vindigni A, Mosammaparast N. Defining and Modulating \u201cBRCAness.\u201d Trends Cell Biol. 2019;29(9):740\u201351.","journal-title":"Trends Cell Biol"},{"issue":"8","key":"1787_CR53","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1158\/0008-5472.CAN-23-0628","volume":"83","author":"J Murai","year":"2023","unstructured":"Murai J, Pommier Y. BRCAness, Homologous Recombination Deficiencies, and Synthetic Lethality. Cancer Res. 2023;83(8):1173\u20134.","journal-title":"Cancer Res"},{"issue":"4","key":"1787_CR54","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1158\/1078-0432.CCR-14-1894","volume":"21","author":"PC Schouten","year":"2015","unstructured":"Schouten PC, Marme F, Aulmann S, Sinn HP, van Essen HF, Ylstra B, et al. Breast cancers with a BRCA1-like DNA copy number profile recur less often than expected after high-dose alkylating chemotherapy. Clin Cancer Res. 2015;21(4):763\u201370.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"1787_CR55","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1038\/nrc1457","volume":"4","author":"N Turner","year":"2004","unstructured":"Turner N, Tutt A, Ashworth A. Hallmarks of \u201cBRCAness\u201d in sporadic cancers. Nat Rev Cancer. 2004;4(10):814\u20139.","journal-title":"Nat Rev Cancer"},{"key":"1787_CR56","doi-asserted-by":"publisher","DOI":"10.1200\/PO.22.00085","volume":"6","author":"S Takamatsu","year":"2022","unstructured":"Takamatsu S, Brown JB, Yamaguchi K, Hamanishi J, Yamanoi K, Takaya H, et al. Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types. JCO Precis Oncol. 2022;6: e2200085.","journal-title":"JCO Precis Oncol"},{"issue":"5","key":"1787_CR57","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1093\/annonc\/mdy099","volume":"29","author":"C Cruz","year":"2018","unstructured":"Cruz C, Castroviejo-Bermejo M, Gutierrez-Enriquez S, Llop-Guevara A, Ibrahim YH, Gris-Oliver A, et al. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer. Ann Oncol. 2018;29(5):1203\u201310.","journal-title":"Ann Oncol"},{"issue":"2","key":"1787_CR58","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.cell.2010.03.012","volume":"141","author":"SF Bunting","year":"2010","unstructured":"Bunting SF, Callen E, Wong N, Chen HT, Polato F, Gunn A, et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell. 2010;141(2):243\u201354.","journal-title":"Cell"},{"key":"1787_CR59","doi-asserted-by":"publisher","first-page":"1125021","DOI":"10.3389\/fonc.2023.1125021","volume":"13","author":"C Velazquez","year":"2023","unstructured":"Velazquez C, Orhan E, Tabet I, Fenou L, Orsetti B, Ad\u00e9la\u00efde J, et al. BRCA1-methylated triple negative breast cancers previously exposed to neoadjuvant chemotherapy form RAD51 foci and respond poorly to olaparib. Front Oncol. 2023;13:1125021.","journal-title":"Front Oncol"},{"key":"1787_CR60","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.gene.2019.06.023","volume":"710","author":"E Bouras","year":"2019","unstructured":"Bouras E, Karakioulaki M, Bougioukas KI, Aivaliotis M, Tzimagiorgis G, Chourdakis M. Gene promoter methylation and cancer: An umbrella review. Gene. 2019;710:333\u201340.","journal-title":"Gene"},{"issue":"18","key":"1787_CR61","doi-asserted-by":"publisher","first-page":"3387","DOI":"10.1038\/s41388-018-0660-y","volume":"38","author":"M Panagopoulou","year":"2019","unstructured":"Panagopoulou M, Karaglani M, Balgkouranidou I, Biziota E, Koukaki T, Karamitrousis E, et al. Circulating cell-free DNA in breast cancer: size profiling, levels, and methylation patterns lead to prognostic and predictive classifiers. Oncogene. 2019;38(18):3387\u2013401.","journal-title":"Oncogene"},{"key":"1787_CR62","doi-asserted-by":"crossref","unstructured":"Panagopoulou M, Fanidis D, Aidinis V, Chatzaki E. ENPP2 Methylation in Health and Cancer. International journal of molecular sciences. 2021;22(21).","DOI":"10.3390\/ijms222111958"},{"key":"1787_CR63","doi-asserted-by":"crossref","unstructured":"Panagopoulou M, Esteller M, Chatzaki E. Circulating Cell-Free DNA in Breast Cancer: Searching for Hidden Information towards Precision Medicine. Cancers. 2021a;13(4).","DOI":"10.3390\/cancers13040728"},{"key":"1787_CR64","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/978-1-61779-270-0_17","volume":"780","author":"I Ibragimova","year":"2011","unstructured":"Ibragimova I, Cairns P. Assays for hypermethylation of the BRCA1 gene promoter in tumor cells to predict sensitivity to PARP-inhibitor therapy. Methods Mol Biol. 2011;780:277\u201391.","journal-title":"Methods Mol Biol"},{"issue":"4","key":"1787_CR65","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jmoldx.2023.01.003","volume":"25","author":"N Sahnane","year":"2023","unstructured":"Sahnane N, Rivera D, Libera L, Carnevali I, Banelli B, Facchi S, et al. Pyrosequencing Assay for BRCA1 Methylation Analysis: Results from a Cross-Validation Study. J Mol Diagn. 2023;25(4):217\u201326.","journal-title":"J Mol Diagn"},{"issue":"2","key":"1787_CR66","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s10549-020-05647-w","volume":"181","author":"A Kawachi","year":"2020","unstructured":"Kawachi A, Yamashita S, Okochi-Takada E, Hirakawa A, Tsuda H, Shimomura A, et al. BRCA1 promoter methylation in breast cancer patients is associated with response to olaparib\/eribulin combination therapy. Breast Cancer Res Treat. 2020;181(2):323\u20139.","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"1787_CR67","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.cancergencyto.2004.12.017","volume":"159","author":"CB Wilcox","year":"2005","unstructured":"Wilcox CB, Baysal BE, Gallion HH, Strange MA, DeLoia JA. High-resolution methylation analysis of the BRCA1 promoter in ovarian tumors. Cancer Genet Cytogenet. 2005;159(2):114\u201322.","journal-title":"Cancer Genet Cytogenet"},{"issue":"1","key":"1787_CR68","doi-asserted-by":"publisher","first-page":"R12","DOI":"10.1186\/bcr1858","volume":"10","author":"C Snell","year":"2008","unstructured":"Snell C, Krypuy M, Wong EM, Loughrey MB, Dobrovic A. BRCA1 promoter methylation in peripheral blood DNA of mutation negative familial breast cancer patients with a BRCA1 tumour phenotype. Breast cancer research\u202f: BCR. 2008;10(1):R12.","journal-title":"Breast cancer research : BCR"},{"key":"1787_CR69","doi-asserted-by":"crossref","unstructured":"Oubaddou Y, Oukabli M, Fenniche S, Elktaibi A, Elochi MR, Al Bouzidi A, et al. BRCA1 Promoter Hypermethylation in Malignant Breast Tumors and in the Histologically Normal Adjacent Tissues to the Tumors: Exploring Its Potential as a Biomarker and Its Clinical Significance in a Translational Approach. Genes. 2023;14(9).","DOI":"10.3390\/genes14091680"},{"issue":"6","key":"1787_CR70","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s40291-022-00614-1","volume":"26","author":"B Zheng-Lin","year":"2022","unstructured":"Zheng-Lin B, Rainone M, Varghese AM, Yu KH, Park W, Berger M, et al. Methylation Analyses Reveal Promoter Hypermethylation as a Rare Cause of \u201cSecond Hit\u201d in Germline BRCA1-Associated Pancreatic Ductal Adenocarcinoma. Mol Diagn Ther. 2022;26(6):645\u201353.","journal-title":"Mol Diagn Ther"},{"issue":"4","key":"1787_CR71","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.3892\/ol.2015.2908","volume":"9","author":"Q Li","year":"2015","unstructured":"Li Q, Wei W, Jiang YI, Yang H, Liu J. Promoter methylation and expression changes of BRCA1 in cancerous tissues of patients with sporadic breast cancer. Oncol Lett. 2015;9(4):1807\u201313.","journal-title":"Oncol Lett"},{"key":"1787_CR72","first-page":"175883592312205","volume":"16","author":"F Geissler","year":"2024","unstructured":"Geissler F, Nesic K, Kondrashova O, Dobrovic A, Swisher EM, Scott CL, et al. The role of aberrant DNA methylation in cancer initiation and clinical impacts. 2024;16:17588359231220512.","journal-title":"The role of aberrant DNA methylation in cancer initiation and clinical impacts"},{"issue":"4","key":"1787_CR73","doi-asserted-by":"publisher","first-page":"R38","DOI":"10.1186\/bcr1522","volume":"8","author":"V Birgisdottir","year":"2006","unstructured":"Birgisdottir V, Stefansson OA, Bodvarsdottir SK, Hilmarsdottir H, Jonasson JG, Eyfjord JE. Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer. Breast cancer research\u202f: BCR. 2006;8(4):R38.","journal-title":"Breast cancer research : BCR"},{"key":"1787_CR74","doi-asserted-by":"crossref","unstructured":"Stefansson OA, Hilmarsdottir H, Olafsdottir K, Tryggvadottir L, Sverrisdottir A, Johannsson OT, et al. BRCA1 Promoter Methylation Status in 1031 Primary Breast Cancers Predicts Favorable Outcomes Following Chemotherapy. JNCI cancer spectrum. 2020;4(2):pkz100.","DOI":"10.1093\/jncics\/pkz100"},{"issue":"9","key":"1787_CR75","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1111\/j.1349-7006.2009.01225.x","volume":"100","author":"Y Chen","year":"2009","unstructured":"Chen Y, Zhou J, Xu Y, Li Z, Wen X, Yao L, et al. BRCA1 promoter methylation associated with poor survival in Chinese patients with sporadic breast cancer. Cancer Sci. 2009;100(9):1663\u20137.","journal-title":"Cancer Sci"},{"issue":"1","key":"1787_CR76","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.1038\/s41467-020-17537-2","volume":"11","author":"D Glodzik","year":"2020","unstructured":"Glodzik D, Bosch A, Hartman J, Aine M, Vallon-Christersson J, Reutersw\u00e4rd C, et al. Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers. Nat Commun. 2020;11(1):3747.","journal-title":"Nat Commun"},{"issue":"11","key":"1787_CR77","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1001\/jamaoncol.2022.3846","volume":"8","author":"PE Lonning","year":"2022","unstructured":"Lonning PE, Nikolaienko O, Pan K, Kurian AW, Eikesdal HP, Pettinger M, et al. Constitutional BRCA1 Methylation and Risk of Incident Triple-Negative Breast Cancer and High-grade Serous Ovarian Cancer. JAMA Oncol. 2022;8(11):1579\u201387.","journal-title":"JAMA Oncol"},{"issue":"3","key":"1787_CR78","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s10549-017-4552-6","volume":"167","author":"RC Brianese","year":"2018","unstructured":"Brianese RC, Nakamura KDM, Almeida F, Ramalho RF, Barros BDF, Ferreira ENE, et al. BRCA1 deficiency is a recurrent event in early-onset triple-negative breast cancer: a comprehensive analysis of germline mutations and somatic promoter methylation. Breast Cancer Res Treat. 2018;167(3):803\u201314.","journal-title":"Breast Cancer Res Treat"},{"issue":"16","key":"1787_CR79","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.1158\/1078-0432.CCR-22-3328","volume":"29","author":"F Blanc-Durand","year":"2023","unstructured":"Blanc-Durand F, Tang R, Pommier M, Nashvi M, Cotteret S, Genestie C, et al. Clinical Relevance of BRCA1 Promoter Methylation Testing in Patients with Ovarian Cancer. Clinical cancer research\u202f: an official journal of the American Association for Cancer Research. 2023;29(16):3124\u20139.","journal-title":"Clinical cancer research : an official journal of the American Association for Cancer Research"},{"key":"1787_CR80","doi-asserted-by":"crossref","unstructured":"Pradjatmo H, Dasuki D, Anwar M, Mubarika S, Harijadi. Methylation status and immunohistochemistry of BRCA1 in epithelial ovarian cancer. Asian Pacific journal of cancer prevention : APJCP. 2014;15(21):9479\u201385.","DOI":"10.7314\/APJCP.2014.15.21.9479"},{"key":"1787_CR81","doi-asserted-by":"crossref","unstructured":"Ruscito I, Dimitrova D, Vasconcelos I, Gellhaus K, Schwachula T, Bellati F, et al. BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients--a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD). European journal of cancer (Oxford, England : 1990). 2014;50(12):2090\u20138.","DOI":"10.1016\/j.ejca.2014.05.001"},{"issue":"13","key":"1787_CR82","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.1158\/1078-0432.CCR-10-0150","volume":"16","author":"N Bednarz","year":"2010","unstructured":"Bednarz N, Eltze E, Semjonow A, Rink M, Andreas A, Mulder L, et al. BRCA1 loss preexisting in small subpopulations of prostate cancer is associated with advanced disease and metastatic spread to lymph nodes and peripheral blood. Clinical cancer research\u202f: an official journal of the American Association for Cancer Research. 2010;16(13):3340\u20138.","journal-title":"Clinical cancer research : an official journal of the American Association for Cancer Research"},{"issue":"5","key":"1787_CR83","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.pan.2021.03.015","volume":"21","author":"C Zhou","year":"2021","unstructured":"Zhou C, Porter N, Borges M, Gauthier C, Ferguson L, Huang B, et al. Examination of ATM, BRCA1, and BRCA2 promoter methylation in patients with pancreatic cancer. Pancreatology. 2021;21(5):938\u201341.","journal-title":"Pancreatology"},{"issue":"6","key":"1787_CR84","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1093\/carcin\/bgi361","volume":"27","author":"DF Peng","year":"2006","unstructured":"Peng DF, Kanai Y, Sawada M, Ushijima S, Hiraoka N, Kitazawa S, et al. DNA methylation of multiple tumor-related genes in association with overexpression of DNA methyltransferase 1 (DNMT1) during multistage carcinogenesis of the pancreas. Carcinogenesis. 2006;27(6):1160\u20138.","journal-title":"Carcinogenesis"},{"issue":"5","key":"1787_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2022.101880","volume":"46","author":"R Abdallah","year":"2022","unstructured":"Abdallah R, Zhao S, Garinet S, Hormigos K, Le Corre D, Cros J, et al. BRCA1 and RAD51C promotor methylation in human resectable pancreatic adenocarcinoma. Clin Res Hepatol Gastroenterol. 2022;46(5): 101880.","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"5","key":"1787_CR86","doi-asserted-by":"publisher","first-page":"638","DOI":"10.4161\/epi.6.5.15667","volume":"6","author":"OA Stefansson","year":"2011","unstructured":"Stefansson OA, Jonasson JG, Olafsdottir K, Hilmarsdottir H, Olafsdottir G, Esteller M, et al. CpG island hypermethylation of BRCA1 and loss of pRb as co-occurring events in basal\/triple-negative breast cancer. Epigenetics. 2011;6(5):638\u201349.","journal-title":"Epigenetics"},{"issue":"7","key":"1787_CR87","first-page":"1887","volume":"19","author":"TL Vu","year":"2018","unstructured":"Vu TL, Nguyen TT, Doan VTH, Vo LTT. Methylation Profiles of BRCA1, RASSF1A and GSTP1 in Vietnamese Women with Breast Cancer. Asian Pac J Cancer Prev. 2018;19(7):1887\u201393.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"16","key":"1787_CR88","doi-asserted-by":"publisher","first-page":"5349","DOI":"10.1158\/1078-0432.CCR-04-0555","volume":"10","author":"P Parrella","year":"2004","unstructured":"Parrella P, Poeta ML, Gallo AP, Prencipe M, Scintu M, Apicella A, et al. Nonrandom distribution of aberrant promoter methylation of cancer-related genes in sporadic breast tumors. Clin Cancer Res. 2004;10(16):5349\u201354.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1787_CR89","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s10549-008-0121-3","volume":"116","author":"T Kontorovich","year":"2009","unstructured":"Kontorovich T, Cohen Y, Nir U, Friedman E. Promoter methylation patterns of ATM, ATR, BRCA1, BRCA2 and p53 as putative cancer risk modifiers in Jewish BRCA1\/BRCA2 mutation carriers. Breast Cancer Res Treat. 2009;116(1):195\u2013200.","journal-title":"Breast Cancer Res Treat"},{"key":"1787_CR90","doi-asserted-by":"crossref","unstructured":"Panagopoulou M, Karaglani M, Manolopoulos VG, Iliopoulos I, Tsamardinos I, Chatzaki E. Deciphering the Methylation Landscape in Breast Cancer: Diagnostic and Prognostic Biosignatures through Automated Machine Learning. Cancers. 2021;13(7).","DOI":"10.3390\/cancers13071677"},{"issue":"3","key":"1787_CR91","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s10549-013-2774-9","volume":"142","author":"L Wu","year":"2013","unstructured":"Wu L, Wang F, Xu R, Zhang S, Peng X, Feng Y, et al. Promoter methylation of BRCA1 in the prognosis of breast cancer: a meta-analysis. Breast Cancer Res Treat. 2013;142(3):619\u201327.","journal-title":"Breast Cancer Res Treat"},{"key":"1787_CR92","doi-asserted-by":"crossref","unstructured":"Azzollini J, Pesenti C, Pizzamiglio S, Fontana L, Guarino C, Peissel B, et al. Constitutive BRCA1 Promoter Hypermethylation Can Be a Predisposing Event in Isolated Early-Onset Breast Cancer. Cancers. 2019;11(1).","DOI":"10.3390\/cancers11010058"},{"issue":"2","key":"1787_CR93","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s00432-010-0957-x","volume":"137","author":"TC de Ruijter","year":"2011","unstructured":"de Ruijter TC, Veeck J, de Hoon JP, van Engeland M, Tjan-Heijnen VC. Characteristics of triple-negative breast cancer. J Cancer Res Clin Oncol. 2011;137(2):183\u201392.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1787_CR94","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.836417","volume":"9","author":"NM Almansour","year":"2022","unstructured":"Almansour NM. Triple-Negative Breast Cancer: A Brief Review About Epidemiology, Risk Factors, Signaling Pathways, Treatment and Role of Artificial Intelligence. Front Mol Biosci. 2022;9: 836417.","journal-title":"Front Mol Biosci"},{"issue":"25","key":"1787_CR95","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.18632\/oncotarget.26818","volume":"10","author":"N Bednarz-Knoll","year":"2019","unstructured":"Bednarz-Knoll N, Eltze E, Semjonow A, Brandt B. BRCAness in prostate cancer. Oncotarget. 2019;10(25):2421\u20132.","journal-title":"Oncotarget"},{"issue":"1","key":"1787_CR96","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","volume":"18","author":"EM Swisher","year":"2017","unstructured":"Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 2017;18(1):75\u201387.","journal-title":"Lancet Oncol"},{"issue":"12","key":"1787_CR97","doi-asserted-by":"publisher","first-page":"3615","DOI":"10.1002\/1878-0261.13108","volume":"15","author":"M Elazezy","year":"2021","unstructured":"Elazezy M, Prieske K, Kluwe L, Oliveira-Ferrer L, Peine S, Muller V, et al. BRCA1 promoter hypermethylation on circulating tumor DNA correlates with improved survival of patients with ovarian cancer. Mol Oncol. 2021;15(12):3615\u201325.","journal-title":"Mol Oncol"},{"issue":"9","key":"1787_CR98","doi-asserted-by":"publisher","first-page":"4403","DOI":"10.7150\/thno.53737","volume":"11","author":"Y Wang","year":"2021","unstructured":"Wang Y, Zhang Y, Huang Y, Chen C, Zhang X, Xing Y, et al. Intratumor heterogeneity of breast cancer detected by epialleles shows association with hypoxic microenvironment. Theranostics. 2021;11(9):4403\u201320.","journal-title":"Theranostics"},{"key":"1787_CR99","doi-asserted-by":"publisher","first-page":"6275","DOI":"10.2147\/CMAR.S206817","volume":"11","author":"M Ashour","year":"2019","unstructured":"Ashour M, Ezzat SH. Frequency of germline mutations in BRCA1 and BRCA2 in ovarian cancer patients and their effect on treatment outcome. Cancer management and research. 2019;11:6275\u201384.","journal-title":"Cancer management and research"},{"issue":"11","key":"1787_CR100","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/nrc2946","volume":"10","author":"DD Bowtell","year":"2010","unstructured":"Bowtell DD. The genesis and evolution of high-grade serous ovarian cancer. Nat Rev Cancer. 2010;10(11):803\u20138.","journal-title":"Nat Rev Cancer"},{"key":"1787_CR101","doi-asserted-by":"crossref","unstructured":"Nesic K, Krais JJ, Vandenberg CJ, Wang Y, Patel P, Cai KQ, et al. BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance. medRxiv : the preprint server for health sciences. 2023.","DOI":"10.1101\/2023.03.20.23287465"},{"issue":"24","key":"1787_CR102","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1001\/jama.2017.7248","volume":"317","author":"MS Litwin","year":"2017","unstructured":"Litwin MS, Tan HJ. The Diagnosis and Treatment of Prostate Cancer: A Review. JAMA. 2017;317(24):2532\u201342.","journal-title":"JAMA"},{"issue":"4","key":"1787_CR103","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41585-022-00680-4","volume":"20","author":"P Rajwa","year":"2023","unstructured":"Rajwa P, Quhal F, Pradere B, Gandaglia G, Ploussard G, Leapman MS, et al. Prostate cancer risk, screening and management in patients with germline BRCA1\/2 mutations. Nat Rev Urol. 2023;20(4):205\u201316.","journal-title":"Nat Rev Urol"},{"issue":"3","key":"1787_CR104","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1002\/ijc.31905","volume":"144","author":"A Omari","year":"2019","unstructured":"Omari A, Nastaly P, Stoupiec S, Balabas A, Dabrowska M, Bielinska B, et al. Somatic aberrations of BRCA1 gene are associated with ALDH1, EGFR, and tumor progression in prostate cancer. Int J Cancer. 2019;144(3):607\u201314.","journal-title":"Int J Cancer"},{"issue":"31","key":"1787_CR105","doi-asserted-by":"publisher","first-page":"10802","DOI":"10.3748\/wjg.v20.i31.10802","volume":"20","author":"A Bilici","year":"2014","unstructured":"Bilici A. Prognostic factors related with survival in patients with pancreatic adenocarcinoma. World J Gastroenterol. 2014;20(31):10802\u201312.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"1787_CR106","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13014-019-1345-6","volume":"14","author":"M Orth","year":"2019","unstructured":"Orth M, Metzger P, Gerum S, Mayerle J, Schneider G, Belka C, et al. Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches. Radiat Oncol. 2019;14(1):141.","journal-title":"Radiat Oncol"},{"issue":"2","key":"1787_CR107","first-page":"409","volume":"60","author":"G Lal","year":"2000","unstructured":"Lal G, Liu G, Schmocker B, Kaurah P, Ozcelik H, Narod SA, et al. Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations. Cancer Res. 2000;60(2):409\u201316.","journal-title":"Cancer Res"},{"issue":"12","key":"1787_CR108","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1038\/bjc.2012.483","volume":"107","author":"J Iqbal","year":"2012","unstructured":"Iqbal J, Ragone A, Lubinski J, Lynch HT, Moller P, Ghadirian P, et al. The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2012;107(12):2005\u20139.","journal-title":"Br J Cancer"},{"issue":"6","key":"1787_CR109","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/bjc.2017.19","volume":"116","author":"T Golan","year":"2017","unstructured":"Golan T, Sella T, O\u2019Reilly EM, Katz MH, Epelbaum R, Kelsen DP, et al. Overall survival and clinical characteristics of BRCA mutation carriers with stage I\/II pancreatic cancer. Br J Cancer. 2017;116(6):697\u2013702.","journal-title":"Br J Cancer"},{"issue":"9","key":"1787_CR110","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/s41571-022-00660-y","volume":"19","author":"A Tivey","year":"2022","unstructured":"Tivey A, Church M, Rothwell D, Dive C, Cook N. Circulating tumour DNA - looking beyond the blood. Nat Rev Clin Oncol. 2022;19(9):600\u201312.","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"1787_CR111","doi-asserted-by":"publisher","first-page":"14079","DOI":"10.1002\/jcp.28097","volume":"234","author":"M Panagopoulou","year":"2019","unstructured":"Panagopoulou M, Karaglani M, Balgkouranidou I, Pantazi C, Kolios G, Kakolyris S, et al. Circulating cell-free DNA release in vitro: kinetics, size profiling, and cancer-related gene methylation. J Cell Physiol. 2019;234(8):14079\u201389.","journal-title":"J Cell Physiol"},{"key":"1787_CR112","doi-asserted-by":"crossref","unstructured":"Panagopoulou M, Drosouni A, Fanidis D, Karaglani M, Balgkouranidou I, Xenidis N, et al. ENPP2 Promoter Methylation Correlates with Decreased Gene Expression in Breast Cancer: Implementation as a Liquid Biopsy Biomarker. International journal of molecular sciences. 2022;23(7).","DOI":"10.3390\/ijms23073717"},{"key":"1787_CR113","doi-asserted-by":"crossref","unstructured":"Papadakis VM, Cheimonidi C, Panagopoulou M, Karaglani M, Apalaki P, Katsara K, et al. Label-Free Human Disease Characterization through Circulating Cell-Free DNA Analysis Using Raman Spectroscopy. International journal of molecular sciences. 2023;24(15).","DOI":"10.3390\/ijms241512384"},{"issue":"1","key":"1787_CR114","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13045-022-01351-y","volume":"15","author":"M Nikanjam","year":"2022","unstructured":"Nikanjam M, Kato S, Kurzrock R. Liquid biopsy: current technology and clinical applications. J Hematol Oncol. 2022;15(1):131.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"1787_CR115","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/ijc.33217","volume":"148","author":"I Heidrich","year":"2021","unstructured":"Heidrich I, Ackar L, Mossahebi Mohammadi P, Pantel K. Liquid biopsies: Potential and challenges. Int J Cancer. 2021;148(3):528\u201345.","journal-title":"Int J Cancer"},{"key":"1787_CR116","doi-asserted-by":"crossref","unstructured":"S SK, Swamy SN, Premalatha CS, Pallavi VR, Gawari R. Aberrant Promoter Hypermethylation of RASSF1a and BRCA1 in Circulating Cell-Free Tumor DNA Serves as a Biomarker of Ovarian Carcinoma. Asian Pacific journal of cancer prevention : APJCP. 2019;20(10):3001\u20135.","DOI":"10.31557\/APJCP.2019.20.10.3001"},{"key":"1787_CR117","doi-asserted-by":"crossref","unstructured":"Reye G, Huang X, Britt KL, Meinert C, Blick T, Xu Y, et al. RASSF1A Suppression as a Potential Regulator of Mechano-Pathobiology Associated with Mammographic Density in BRCA Mutation Carriers. Cancers (Basel). 2021;13(13).","DOI":"10.3390\/cancers13133251"},{"key":"1787_CR118","doi-asserted-by":"crossref","unstructured":"Ibanez de Caceres I, Battagli C, Esteller M, Herman JG, Dulaimi E, Edelson MI, et al. Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer research. 2004;64(18):6476\u201381.","DOI":"10.1158\/0008-5472.CAN-04-1529"},{"issue":"1","key":"1787_CR119","doi-asserted-by":"publisher","first-page":"60","DOI":"10.2353\/jmoldx.2009.080072","volume":"11","author":"A Melnikov","year":"2009","unstructured":"Melnikov A, Scholtens D, Godwin A, Levenson V. Differential methylation profile of ovarian cancer in tissues and plasma. J Mol Diagn. 2009;11(1):60\u20135.","journal-title":"J Mol Diagn"},{"issue":"1","key":"1787_CR120","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41698-021-00198-9","volume":"5","author":"K Cristall","year":"2021","unstructured":"Cristall K, Bidard FC, Pierga JY, Rauh MJ, Popova T, Sebbag C, et al. A DNA methylation-based liquid biopsy for triple-negative breast cancer. NPJ Precis Oncol. 2021;5(1):53.","journal-title":"NPJ Precis Oncol"},{"issue":"Suppl 1","key":"1787_CR121","doi-asserted-by":"publisher","first-page":"S2217","DOI":"10.3233\/BME-151527","volume":"26","author":"L Liu","year":"2015","unstructured":"Liu L, Sun L, Li C, Li X, Zhang Y, Yu Y, et al. Quantitative detection of methylation of FHIT and BRCA1 promoters in the serum of ductal breast cancer patients. Bio-Med Mater Eng. 2015;26(Suppl 1):S2217\u201322.","journal-title":"Bio-Med Mater Eng"},{"issue":"11","key":"1787_CR122","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.4161\/epi.22220","volume":"7","author":"SR Sturgeon","year":"2012","unstructured":"Sturgeon SR, Balasubramanian R, Schairer C, Muss HB, Ziegler RG, Arcaro KF. Detection of promoter methylation of tumor suppressor genes in serum DNA of breast cancer cases and benign breast disease controls. Epigenetics. 2012;7(11):1258\u201367.","journal-title":"Epigenetics"},{"issue":"1","key":"1787_CR123","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13058-020-1250-9","volume":"22","author":"TC de Ruijter","year":"2020","unstructured":"de Ruijter TC, van der Heide F, Smits KM, Aarts MJ, van Engeland M, Heijnen VCG. Prognostic DNA methylation markers for hormone receptor breast cancer: a systematic review. Breast Cancer Res. 2020;22(1):13.","journal-title":"Breast Cancer Res"},{"key":"1787_CR124","doi-asserted-by":"crossref","unstructured":"Yen J, Chen S, Jenkins C, Overstreet B, Fu Y, Zhao J, et al. Abstract 6603: BRCA1 promoter methylation in sporadic breast cancer patients detected by liquid biopsy. Cancer research. 2023;83(7_Supplement):6603-.","DOI":"10.1158\/1538-7445.AM2023-6603"},{"issue":"9","key":"1787_CR125","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.7150\/jca.93184","volume":"15","author":"T Koukaki","year":"2024","unstructured":"Koukaki T, Balgkouranidou I, Biziota E, Karayiannakis A, Bolanaki H, Karamitrousis E, et al. Prognostic significance of BRCA1 and BRCA2 methylation status in circulating cell-free DNA of Pancreatic Cancer patients. J Cancer. 2024;15(9):2573\u20139.","journal-title":"J Cancer"},{"issue":"6","key":"1787_CR126","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1002\/1878-0261.12869","volume":"15","author":"A Vasseur","year":"2021","unstructured":"Vasseur A, Kiavue N, Bidard FC, Pierga JY, Cabel L. Clinical utility of circulating tumor cells: an update. Mol Oncol. 2021;15(6):1647\u201366.","journal-title":"Mol Oncol"},{"issue":"3","key":"1787_CR127","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.molonc.2012.12.007","volume":"7","author":"B Stordal","year":"2013","unstructured":"Stordal B, Timms K, Farrelly A, Gallagher D, Busschots S, Renaud M, et al. BRCA1\/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation. Mol Oncol. 2013;7(3):567\u201379.","journal-title":"Mol Oncol"},{"issue":"3","key":"1787_CR128","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s11523-021-00796-4","volume":"16","author":"L Cortesi","year":"2021","unstructured":"Cortesi L, Rugo HS, Jackisch C. An Overview of PARP Inhibitors for the Treatment of Breast Cancer. Target Oncol. 2021;16(3):255\u201382.","journal-title":"Target Oncol"},{"issue":"8","key":"1787_CR129","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1093\/annonc\/mdw142","volume":"27","author":"M Moschetta","year":"2016","unstructured":"Moschetta M, George A, Kaye SB, Banerjee S. BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer. Ann Oncol. 2016;27(8):1449\u201355.","journal-title":"Ann Oncol"},{"key":"1787_CR130","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1186\/1471-2407-13-523","volume":"13","author":"W Jacot","year":"2013","unstructured":"Jacot W, Thezenas S, Senal R, Viglianti C, Laberenne AC, Lopez-Crapez E, et al. BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer. BMC Cancer. 2013;13:523.","journal-title":"BMC Cancer"},{"issue":"1","key":"1787_CR131","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13046-021-01930-w","volume":"40","author":"X Zhu","year":"2021","unstructured":"Zhu X, Chen L, Huang B, Li X, Yang L, Hu X, et al. Efficacy and mechanism of the combination of PARP and CDK4\/6 inhibitors in the treatment of triple-negative breast cancer. J Exp Clin Cancer Res. 2021;40(1):122.","journal-title":"J Exp Clin Cancer Res"},{"issue":"9","key":"1787_CR132","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/S1470-2045(11)70214-5","volume":"12","author":"KA Gelmon","year":"2011","unstructured":"Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011;12(9):852\u201361.","journal-title":"Lancet Oncol"},{"key":"1787_CR133","doi-asserted-by":"crossref","unstructured":"Veeck J, Ropero S, Setien F, Gonzalez-Suarez E, Osorio A, Benitez J, et al. BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors. J Clin Oncol. 2010;28(29):e563\u20134; author reply e5\u20136.","DOI":"10.1200\/JCO.2010.30.1010"},{"issue":"2","key":"1787_CR134","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.annonc.2020.11.009","volume":"32","author":"HP Eikesdal","year":"2021","unstructured":"Eikesdal HP, Yndestad S, Elzawahry A, Llop-Guevara A, Gilje B, Blix ES, et al. Olaparib monotherapy as primary treatment in unselected triple negative breast cancer. Ann Oncol. 2021;32(2):240\u20139.","journal-title":"Ann Oncol"},{"issue":"1","key":"1787_CR135","doi-asserted-by":"publisher","first-page":"3970","DOI":"10.1038\/s41467-018-05564-z","volume":"9","author":"O Kondrashova","year":"2018","unstructured":"Kondrashova O, Topp M, Nesic K, Lieschke E, Ho G-Y, Harrell MI, et al. Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nat Commun. 2018;9(1):3970.","journal-title":"Nat Commun"},{"key":"1787_CR136","doi-asserted-by":"crossref","unstructured":"Dimitrova D, Ruscito I, Olek S, Richter R, Hellwag A, Turbachova I, et al. Germline mutations of BRCA1 gene exon 11 are not associated with platinum response neither with survival advantage in patients with primary ovarian cancer: understanding the clinical importance of one of the biggest human exons. A study of the Tumor Bank Ovarian Cancer (TOC) Consortium. Tumour Biol. 2016;37(9):12329\u201337.","DOI":"10.1007\/s13277-016-5109-8"},{"issue":"8","key":"1787_CR137","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1172\/JCI70196","volume":"126","author":"R Drost","year":"2016","unstructured":"Drost R, Dhillon KK, van der Gulden H, van der Heijden I, Brandsma I, Cruz C, et al. BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1. J Clin Invest. 2016;126(8):2903\u201318.","journal-title":"J Clin Invest"},{"key":"1787_CR138","doi-asserted-by":"crossref","unstructured":"Jacot W, Lopez-Crapez E, Mollevi C, Boissiere-Michot F, Simony-Lafontaine J, Ho-Pun-Cheung A, et al. BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer. Cancers (Basel). 2020;12(4).","DOI":"10.3390\/cancers12040828"},{"issue":"10","key":"1787_CR139","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1038\/nsmb.1915","volume":"17","author":"R Buisson","year":"2010","unstructured":"Buisson R, Dion-Cote AM, Coulombe Y, Launay H, Cai H, Stasiak AZ, et al. Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination. Nat Struct Mol Biol. 2010;17(10):1247\u201354.","journal-title":"Nat Struct Mol Biol"},{"issue":"18","key":"1787_CR140","doi-asserted-by":"publisher","first-page":"4517","DOI":"10.1158\/1078-0432.CCR-10-0526","volume":"16","author":"CM Annunziata","year":"2010","unstructured":"Annunziata CM, O\u2019Shaughnessy J. Poly (ADP-ribose) polymerase as a novel therapeutic target in cancer. Clin Cancer Res. 2010;16(18):4517\u201326.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1787_CR141","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1093\/jnci\/djq509","volume":"103","author":"Y Drew","year":"2011","unstructured":"Drew Y, Mulligan EA, Vong WT, Thomas HD, Kahn S, Kyle S, et al. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. J Natl Cancer Inst. 2011;103(4):334\u201346.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"1787_CR142","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13058-017-0856-z","volume":"19","author":"S Vos","year":"2017","unstructured":"Vos S, Moelans CB, van Diest PJ. BRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers. Breast Cancer Res. 2017;19(1):64.","journal-title":"Breast Cancer Res"},{"key":"1787_CR143","first-page":"23","volume":"7","author":"M Guo","year":"2019","unstructured":"Guo M, Peng Y, Gao A, Du C, Herman JG. Epigenetic heterogeneity in cancer Biomark Res. 2019;7:23.","journal-title":"Epigenetic heterogeneity in cancer Biomark Res"},{"issue":"47","key":"1787_CR144","doi-asserted-by":"publisher","first-page":"83063","DOI":"10.18632\/oncotarget.20945","volume":"8","author":"K Prieske","year":"2017","unstructured":"Prieske K, Prieske S, Joosse SA, Trillsch F, Grimm D, Burandt E, et al. Loss of BRCA1 promotor hypermethylation in recurrent high-grade ovarian cancer. Oncotarget. 2017;8(47):83063\u201374.","journal-title":"Oncotarget"},{"key":"1787_CR145","doi-asserted-by":"crossref","unstructured":"Harvey-Jones E, Raghunandan M, Robbez-Masson L, Thanussuyah A, Liccardo R, Yablonovitch A, et al. Abstract 6094: Longitudinal analysis of PARP inhibitor and platinum resistance in BRCA1\/2m breast cancer using liquid biopsy. Cancer research. 2023;83(7_Supplement):6094-.","DOI":"10.1158\/1538-7445.AM2023-6094"},{"issue":"6","key":"1787_CR146","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.annonc.2021.03.196","volume":"32","author":"A Jayaram","year":"2021","unstructured":"Jayaram A, Wingate A, Wetterskog D, Wheeler G, Sternberg CN, Jones R, et al. Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial. Ann Oncol. 2021;32(6):726\u201335.","journal-title":"Ann Oncol"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-024-01787-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13148-024-01787-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-024-01787-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T07:02:36Z","timestamp":1733468556000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalepigeneticsjournal.biomedcentral.com\/articles\/10.1186\/s13148-024-01787-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,6]]},"references-count":146,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1787"],"URL":"https:\/\/doi.org\/10.1186\/s13148-024-01787-8","relation":{},"ISSN":["1868-7083"],"issn-type":[{"value":"1868-7083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,6]]},"assertion":[{"value":"12 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"178"}}